NECTAR LIFESCIENCES
|
NECTAR LIFESCIENCES Last 5 Year Financial Ratios History
[Consolidated]
| Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | -1.08 | 1.12 | -3.27 | 1.44 | 2.12 |
| CEPS(Rs) | 1.56 | 3.66 | -0.58 | 4.13 | 4.94 |
| DPS(Rs) | - | - | - | 0.05 | 0.05 |
| Book NAV/Share(Rs) | 47.47 | 48.51 | 47.36 | 50.66 | 49.28 |
| Tax Rate(%) | 42.99 | 26.51 | 13.57 | 15.16 | 19.08 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 3.03 | 8.23 | 5.75 | 8.31 | 8.49 |
| EBIT Margin(%) | 2.12 | 5.86 | 1.55 | 6.18 | 6.65 |
| Pre Tax Margin(%) | -2.43 | 1.77 | -4.81 | 1.42 | 1.89 |
| PAT Margin (%) | -1.38 | 1.30 | -4.15 | 1.20 | 1.53 |
| Cash Profit Margin (%) | 2.00 | 4.26 | -0.74 | 3.50 | 3.56 |
| Performance Ratios | |||||
| ROA(%) | -1.06 | 1.05 | -2.93 | 1.19 | 1.75 |
| ROE(%) | -2.25 | 2.33 | -6.67 | 2.84 | 4.40 |
| ROCE(%) | 1.97 | 5.77 | 1.41 | 8.32 | 10.29 |
| Asset Turnover(x) | 0.77 | 0.81 | 0.70 | 0.99 | 1.15 |
| Sales/Fixed Asset(x) | 1.12 | 1.23 | 1.15 | 1.76 | 2.11 |
| Working Capital/Sales(x) | 5.13 | 5.49 | 34.29 | 7.20 | 8.43 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.89 | 0.81 | 0.87 | 0.57 | 0.47 |
| Receivable days | 75.92 | 77.89 | 79.75 | 65.92 | 68.64 |
| Inventory Days | 139.23 | 118.26 | 161.98 | 130.89 | 104.21 |
| Payable days | 109.47 | 107.25 | 137.11 | 99.25 | 84.19 |
| Valuation Parameters | |||||
| PER(x) | - | 21.53 | - | 6.86 | 8.06 |
| PCE(x) | 10.18 | 6.58 | -32.06 | 2.40 | 3.46 |
| Price/Book(x) | 0.33 | 0.50 | 0.39 | 0.20 | 0.35 |
| Yield(%) | - | - | - | 0.51 | 0.29 |
| EV/Net Sales(x) | 0.72 | 0.83 | 0.84 | 0.41 | 0.45 |
| EV/Core EBITDA(x) | 11.35 | 8.13 | 11.48 | 4.37 | 4.68 |
| EV/EBIT(x) | 29.46 | 12.24 | 47.49 | 6.00 | 6.12 |
| EV/CE(x) | 0.50 | 0.58 | 0.55 | 0.37 | 0.47 |
| M Cap / Sales | 0.23 | 0.32 | 0.27 | 0.09 | 0.14 |
| Growth Ratio | |||||
| Net Sales Growth(%) | -8.70 | 8.13 | -34.78 | -14.97 | 48.32 |
| Core EBITDA Growth(%) | -43.37 | 50.54 | -49.64 | -17.08 | 11.57 |
| EBIT Growth(%) | -67.17 | 314.00 | -83.30 | -21.10 | 16.34 |
| PAT Growth(%) | -196.55 | 134.19 | -330.47 | -33.22 | -8.94 |
| EPS Growth(%) | -196.55 | 134.19 | -326.70 | -32.11 | -8.94 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.71 | 0.79 | 0.85 | 0.69 | 0.82 |
| Current Ratio(x) | 1.38 | 1.35 | 1.04 | 1.29 | 1.28 |
| Quick Ratio(x) | 0.63 | 0.69 | 0.55 | 0.51 | 0.58 |
| Interest Cover(x) | 0.47 | 1.43 | 0.24 | 1.30 | 1.40 |
| Total Debt/Mcap(x) | 2.12 | 1.59 | 2.17 | 3.51 | 2.36 |
Compare Financial Ratios of peers of NECTAR LIFESCIENCES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| NECTAR LIFESCIENCES | ₹765.8 Cr | 2.1% | 10.2% | 97.5% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹364,831.0 Cr | -0.1% | -2.8% | 50.3% | Stock Analytics | |
| CIPLA | ₹113,471.0 Cr | 4.5% | -3.1% | 52.8% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹103,713.0 Cr | 4.6% | 1.4% | 22.2% | Stock Analytics | |
| DIVIS LABORATORIES | ₹101,960.0 Cr | 4.7% | 10.8% | 18.1% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹95,687.8 Cr | 3.1% | -4.1% | 80.4% | Stock Analytics | |
NECTAR LIFESCIENCES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| NECTAR LIFESCIENCES | 2.1% |
10.2% |
97.5% |
| SENSEX | 1.3% |
2.6% |
24% |
You may also like the below Video Courses
